54B, Tailstoi Town 5238 MT, La city, IA 522364
![](https://www.vitalityhealthsfl.com/wp-content/uploads/2020/03/new-logo-110px-20202.png)
Starting a new course on any drug comes with questions and concerns. At Vitality Health of South Florida, we strive to bring you the research results you are searching for, without the time and effort needed to dig and piece together articles from the internet. Rather, we prefer to go straight to the authorities on the matter.
A Look at Cardiovascular Risk and Semaglutide
All pharmaceutical manufacturers are required to assess the cardiovascular risk of all new therapies being considered to go to market for Type 2 Diabetes.
Semaglutide, a glucagon-like peptide 1, is one such formulation. It has a half-life of one week and lowers blood glucose levels upon injection.
In a multi-center double-blind non-inferiority trial which was conducted across twenty countries 3297 patients who had Type 2 Diabetes were studied. In this control group, the mean age was 65 and they had been treated for diabetes for the last 13.9 years. Their mean glycated hemoglobin level sat at 8.7%.
It is also important to note that 93% of participants had a history of high blood pressure and 60% had a historic notation of ischemic heart disease.
The group was randomly split into two groups of treatment. The first group received a placebo (which is inert and has no effect, yet the patients do not know this). The other group was given injections of Semaglutide 0.5 mg or 1.0mg.
At 104 weeks into the trial, the primary composite outcome of cardiovascular death and the first instance of non-fatal myocardial infarction or stroke had occurred in 6.6% of patients receiving Semaglutide as compared to 8.9% of those who received only a placebo.
This study confirmed the non-inferiority hypothesis. Semaglutide was not associated with any cardiovascular risk and shows promise to actually lower cardiovascular incidence in those with Type 2 Diabetes.
This is wonderfully positive news for anyone considering taking Semaglutide.
Sources: Semaglutide and Cardiovascular Risks | NEJM
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | NEJM
Ready to Get Started?
Visit www.vitalityhealthsfl.com to learn more about the practice and the services we offer.
Give us a call at 1-833-4LOWTEE to schedule your consultation!
We look forward to helping you push through that weight loss barrier and accomplishing your long term health goals!
Want more info? Visit our page on Semaglutide
Have you already been a patient of Vitality Health SFL? We Would Love a Review!